VIDEO: Treatment of metastatic triple-negative breast cancer has 'changed drastically'

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The world of triple negative breast cancer has changed drastically over the past few years and I would argue that there are two main, big themes that changed the landscape of the treatment, one of them has been the introduction of immunotherapy, which is well known in other kinds of cancers, but it made a recent debut in the breast cancer world. This has been a drastic change and we've incorporated immunotherapy in most of standard of care as well as clinical trials at this point. Alongside that, there has been the introduction of antibody drug conjugates and these are really fascinating concepts in the older kind when we talk about the classes of treatment that we use for breast cancer in general, however, the novel new antibody drug conjugates are very promising and they have two, I would say, degrees of freedom. You have the antibody that you designed for a particular protein on the breast cancer cell and then you have the chemotherapy that's piggybacked on that antibody and you can change whatever in either of these two parts. One recent example that got FDA approval last year is instruction of the antibody drug conjugate, Sacituzumab govitecan or Trodelvy which is directed, again, Trop-2 which is the protein expressed on triple negative breast cancer cells. The success of this agent allowed us to explore other antibody drug conjugates, another FDA approval came shortly after for a drug called Trastuzumab deruxtecan or Enhertu which targets HER2 low breast cancer and triple-negative breast cancer serum. And currently there is other drugs, I would say, ovinadothend in clinical trials that are aiming to incorporate different targets in triple negative breast cancer as well as different chemo combinations. Now I'd say these two components, immunotherapy and antibody drug conjugates have really shifted the scene of how we treat triple negative breast cancer in the past few years.